Alphatec Holdings, Inc. (ATEC) is a medical technology company that designs and sells implants, instruments, and imaging systems for the surgical treatment of spinal disorders, including the EOS imaging platform. Averaging roughly 10 current, individually verifiable analyst price targets produces a mean of about $13.50, which rounds to a central target of $14. The targets reviewed range from $8 to $24.
The dispersion is meaningful. Following the company's third-quarter results in late October, several firms trimmed targets sharply. UBS (Neutral) cut to $8.50, BMO Capital downgraded to Market Perform with an $8 target, and TD Cowen lowered to $10, while Needham moved to $12 and Stifel to $11. More constructive views persisted at JPMorgan ($15, Overweight), Lake Street ($14, Buy), and Canaccord Genuity ($16, Buy), while H.C. Wainwright retained a $24 target. The overall analyst consensus remains a Strong Buy, but the wide range signals genuine uncertainty about how quickly growth can re-accelerate. This average is a calculation, not an official published consensus, and it should not be read as a guarantee.
ATEC closed near $7.47 on November 3, 2026, near the bottom of a 52-week range of roughly $6.81 to $23.29. To reach $14, the shares would need to climb about 87% from current levels, a very large move by any standard. The stock fell sharply in late October after the company reported third-quarter revenue of $221.2 million (up 13% year over year but below expectations) and reduced full-year 2026 revenue guidance to approximately $862 million from $882 million. Management attributed the shortfall to lower biologics attachment rates, softer thoracolumbar procedure volumes, EOS timing, and a temporary international supply constraint.
Even so, the underlying demand picture is not broken. Surgical case volume grew roughly 20%, and the company added a record number of new surgeons. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to about $38 million in the quarter, a roughly 17% margin, and free cash flow remained positive. The path toward $14 therefore depends less on the top-line franchise and more on re-accelerating biologics pull-through and stabilizing the thoracolumbar segment.
The stock is trading near its 52-week low around $6.81 after a sharp decline, leaving limited nearby chart support beyond that multi-year trough. The $8 level, which coincides with the BMO and UBS targets, now acts as the first meaningful resistance level; a sustained push above roughly $10 to $12 would be needed to signal a durable recovery toward the mid-teens. The prior high near $23 serves as the long-term ceiling but is not relevant to the near-term objective of $14.
Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms differ, and targets here were revised within days of the earnings report. Investors should watch the next quarterly report for evidence that biologics attachment rates are recovering, any update to the 2026 revenue outlook, adjusted EBITDA margin progression, and free cash flow. Additional analyst revisions, the pace of new-surgeon conversion, and EOS system placements are the most relevant signals for whether the gap toward $14 narrows.
For traders who want a more systematic view of shifting conditions, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Explore the signals to see how an AI-driven lens complements the fundamental picture for names like ATEC.
The central $14 target is an arithmetic mean of current analyst targets rather than a forecast, and it sits roughly 87% above the latest price. The bull case rests on strong case-volume and new-surgeon momentum plus improving margins, while the bear case points to the biologics shortfall, the guidance cut, and wide analyst disagreement ($8 to $24). Reaching $14 is not a near-term assumption but a multi-quarter scenario that hinges on re-accelerating revenue-per-procedure and restoring confidence in the growth algorithm. Investors should treat the target as a reference point and monitor the next earnings report and subsequent analyst revisions before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ATEC has been loosely correlated with SIBN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ATEC jumps, then SIBN could also see price increases.
| Ticker / NAME | Correlation To ATEC | 1D Price Change % | ||
|---|---|---|---|---|
| ATEC | 100% | +0.14% | ||
| SIBN - ATEC | 51% Loosely correlated | -2.90% | ||
| OFIX - ATEC | 45% Loosely correlated | +3.31% | ||
| IRMD - ATEC | 44% Loosely correlated | +0.38% | ||
| ENOV - ATEC | 39% Loosely correlated | +0.14% | ||
| PODD - ATEC | 38% Loosely correlated | +2.14% | ||
More | ||||
| Ticker / NAME | Correlation To ATEC | 1D Price Change % |
|---|---|---|
| ATEC | 100% | +0.14% |
| Health Services category (238 stocks) | 4% Poorly correlated | -1.01% |
| Medical/Nursing Services category (138 stocks) | 4% Poorly correlated | -1.10% |